

Metabolites from the Induced Expression of Cryptic Single Operons Found in the Genome of *Burkholderia pseudomallei*

John B. Biggins,[†] Xiaofei Liu,[†] Zhiyang Feng, and Sean F. Brady^{*}

Laboratory for Genetically Encoded Small Molecules, Howard Hughes Medical Institute, The Rockefeller University, 1230 York Avenue, New York, New York 10065, United States

S Supporting Information

ABSTRACT: Bacterial genome sequencing projects routinely uncover gene clusters that are predicted to encode the biosynthesis of uncharacterized small molecules. A subset of these cryptic genetic elements appears as individual operons. Here we investigate potential single-operon biosynthetic systems found in the genome of the pathogenic bacterium *Burkholderia pseudomallei*. Placing these operons under the control of an inducible promoter led to the production of seven new metabolites. Among the molecules we identified are inhibitors of type-4 phosphodiesterases, suggesting that previously cryptic biosynthetic operons may encode metabolites that could contribute to microbial virulence by disrupting host signaling pathways.

Bacteria rely extensively on low-molecular-weight organic compounds to interact with the world around them, and in the case of pathogenic bacteria, these small molecules can be key components of pathogenesis.^{1,2} Small-molecule biosynthetic gene clusters that do not appear to encode for metabolites previously identified in fermentation-based studies are routinely found in sequenced bacterial genomes.³ These cryptic biosynthetic gene clusters represent candidate pathways from which additional small-molecule virulence factors might be identified in pathogenic bacteria. While the biosynthesis of many small molecules is encoded on large stretches of genomic DNA, consisting of multiple operons, the biosynthesis of some metabolites can require as little as a single gene or operon. Systematically decoupling these short cryptic biosynthetic operons from their native promoters and placing them under the control of well-studied inducible promoters in model bacterial hosts should provide a means to access compounds encoded by previously uncharacterized single-operon, small-molecule biosynthetic systems (Figure 1). An examination of putative cryptic biosynthetic operons found in the genome of *Burkholderia pseudomallei*, the etiological agent of melioidosis,⁴ has led to the identification of two operons that upon induction in *Pseudomonas aeruginosa* confer the production of novel metabolites to this host (Figure 2). Melioidosis is endemic in Southeast Asia and Northern Australia, and because of its historical use in biological weapons programs, *B. pseudomallei* is categorized as a class B select agent by the Centers for Disease Control in the United States.⁴

In total, 13 potential biosynthetic operons were selected by manually examining the genome of *B. pseudomallei* K96243 for




Figure 1. It should be possible to produce metabolites encoded by tightly regulated cryptic single-operon biosynthetic systems using well-controlled inducible promoters in model heterologous hosts.




Figure 2. The positions of potential single-operon biosynthetic systems examined in this study are mapped onto chromosome II of *B. pseudomallei* K96243. Chromosome I did not yield any metabolites and is not shown. Compounds identified in this study are shown in red. Gene clusters either known or predicted to be associated with the production of structurally characterized metabolites in *B. pseudomallei* are tagged with the metabolites they encode (black).^{5–7} A metabolite identified in heterologous expression experiments in *E. coli* using a previously cryptic *B. pseudomallei* operon appears in green.⁸

uncharacterized operons containing genes predicted to encode enzymes with strong links to secondary metabolism, including polyketide synthases (PKS), nonribosomal peptide synthetases (NRPS), acyl-CoA ligases, functional-group transferases, and redox-active proteins (Figure 2 and Table S1 in the Supporting Information). Each operon was PCR-amplified from genomic DNA, cloned under the control of an IPTG-inducible P_{tac} promoter (pMMB67EXPH), and conjugated into *P. aeruginosa* for heterologous expression studies.⁹ *P. aeruginosa* was chosen as the heterologous host for this study because it is easily transformable, grows rapidly, and natively produces a diverse collection of secondary metabolites.

Received: October 6, 2010

Published: January 19, 2011




Figure 3. IPTG-induced expression of either (a) the BTH-II0204–207/BPSS0130–133 operon or (b) the BPSS2111–2113 operon leads to the production of clone-specific metabolites in *P. aeruginosa*. In each case, the control extract was derived from cultures of *P. aeruginosa* transformed with the empty expression vector. (c) *B. thailandensis* E264 grown in LB broth with and without phenylalanine.

All *P. aeruginosa* transformants were grown in LB broth at 30 °C (250 rpm) to an optical density at 600 nm (OD_{600}) of 0.1, at which time the expression of individual operons was induced with 0.1 mM IPTG. After 24–36 h of shaking, induced cultures were extracted with an equal volume of ethyl acetate, and these extracts were then examined for the presence of clone-specific molecules by silica gel thin-layer chromatography. Clone-specific molecules were detected in extracts derived from cultures of *P. aeruginosa* transformed with two operons: BTH-II0204–207/BPSS0130–133 and BPSS2111–2113 (Figure 3a, b).¹⁰ Although subsets of the genes found in these operons are found in other bacterial genomes, both operons appear to be unique to sequenced *Burkholderia* genomes. NMR, high-resolution mass spectrometry, and X-ray crystallography data were used to elucidate the structures of the seven clone-specific metabolites isolated from ethyl acetate extracts of large-scale (6 L) cultures of *P. aeruginosa* expressing these operons (Figure 4).

None of the metabolites identified in this study have been reported previously as natural products. As *B. pseudomallei* is a highly infectious BSL3-level pathogen, it was impractical for us to look for compounds 1–7 in large-scale broth cultures of this organism. *Burkholderia thailandensis* is a close relative of *B. pseudomallei* that is not generally considered to be a human pathogen. However, it is infectious at high titers, which makes it a good low-virulence model for studying *Burkholderia* pathogens in the laboratory.^{11,12} The BTH-II0204–207/BPSS0130–133 operon is found in both *B. pseudomallei* and *B. thailandensis*, so it was possible to look for the products of this operon in cultures of *B. thailandensis* grown under standard conditions. In our initial examination of culture-broth extracts from *B. thailandensis* grown in a variety of minimal and rich media, none of the compounds associated with this operon could be detected by HPLC-MS. We subsequently explored the possibility that the BTH-II0204–207/BPSS0130–133 operon might be induced in the presence of high substrate concentrations.

BTH-II0204–207/BPSS0130–133 is a four-gene operon that is predicted to contain a single NRPS gene, a dehydratase, an




Figure 4. Clone-specific molecules identified in culture broths of *P. aeruginosa* transformed with potential cryptic biosynthetic operons from *Burkholderia* spp.




Figure 5. (a) Initial steps in the biosynthesis of the fungal metabolite terrequinone (8).¹³ (b) Predicted general biosynthetic scheme for 1. Promiscuity of the methyltransferase would account for the varied methylation patterns. The exact roles of the predicted dehydratase and isomerase enzymes remain to be determined.

isomerase, and a methyltransferase (Figure 4, 5b). The closest experimentally defined homologues of the NRPS module are from fungi (40% identity).¹³ In fungal systems, this module carries out the dimerization of deaminated aromatic amino acids to produce tricyclic structures in which the central ring is a hydroxyquinone (Figure 5a).¹³ The NRPS module from the BTH-II0204–207/BPSS0130–133 operon likely carries out a similar dimerization of phenylalanine or a phenylalanine-derived precursor (Figure 5b). Cultures of *B. thailandensis* grown in LB broth were therefore spiked with phenylalanine (10 mM), and extracts from these cultures were examined for the presence of 1–4. As shown in Figure 3c, compound 1 can be found easily in extracts from cultures spiked with phenylalanine. Deletion of the NRPS gene in *B. thailandensis* E264 by targeted mutagenesis¹⁴ abolished the production of 1, confirming the biosynthetic role of this operon (Figure S1 in the Supporting Information).

In cytotoxicity assays run against representative bacteria (*Bacillus subtilis*, *Staphylococcus aureus*, and *Escherichia coli*), *Saccharomyces cerevisiae*, and human HeLa cells, most of these metabolites were inactive. Compounds 1 and 3 showed activity against *B. subtilis* [with minimum inhibitory concentrations (MICs) of 11 and 33 $\mu\text{g}/\text{mL}$, respectively], and 1 also showed mild




Figure 6. (a) Percent activity of a spectrum of phosphodiesterases in the presence of either compound **1** (black) or compound **3** (gray). (b) Terferol (**9**).

activity against *S. cerevisiae* (MIC = 11 $\mu\text{g}/\text{mL}$). A potential biological role for these metabolites was sought by examining the literature for known metabolites with similar structures and known biological activities. Compounds **1**–**4** resemble the *Streptomyces* sp.-derived metabolite terferol (**9**; Figure 6b), which was originally identified in a screen for eukaryotic phosphodiesterase (PDE) inhibitors.^{10,15,16} Compounds **1**–**4** differ from terferol by either the position or number of methyl substituents found on each metabolite.

PDEs terminate signaling of cyclic nucleotide second messengers by hydrolyzing cAMP and/or cGMP to the corresponding inactive 5'-mononucleotides. PDEs are divided into 11 biochemically and pharmacologically distinct enzyme families that are distinguished primarily by differences in substrate preference, structure, and inhibitor sensitivities. Compounds **1** and **3**, the major clone-specific metabolites produced by the BTH-II0204–207/BPSS0130–133 operon in our heterologous expression studies, were assayed for PDE inhibition activity against a panel of purified eukaryotic PDEs. At 100 μM , the dimethylated **3** was largely inactive. At the same concentration, the monomethylated **1** showed activity against PDE11 as well as four out of the five PDE4s that we examined (Figure 6a). The most active derivative, compound **1**, is also the major product we observed in cultures of wild-type *B. thailandensis* spiked with phenylalanine. PDE4s have been implicated in inflammation responses across multiple immune cell types.¹⁷ As a consequence, PDE4 inhibitors have been extensively investigated as potential therapeutics for a number of inflammatory diseases.¹⁸ It has been reported that animals treated with PDE inhibitors (rolipram or aminophylline) show impaired host defenses against pathogenic bacteria.^{19,20} In particular, the PDE4 inhibitor rolipram was found to inhibit tumor necrosis factor α production and neutrophil migration into the site of infection, resulting in earlier lethality and enhanced bacterial load in infected mice. While compound **1** is significantly less active (40 μM MIC for PDE4A1) than optimized synthetic PDE4 inhibitors, the immediate environment adjacent to a pathogen during an infection would likely see a high effective concentration of any secreted metabolite.²¹ The production of PDE4 inhibitors could therefore represent a way by which pathogenic bacteria abrogate host defense mechanisms.

Decoupling individual cryptic biosynthetic operons from their native promoters and activating them with controlled inducible promoters should provide functional access to many simple cryptic gene clusters found in bacterial genomes. In the study of pathogenic bacteria such as *B. pseudomallei*, this strategy provides the added advantage of being able to study metabolites produced by infectious bacteria without having to grow pathogens in the laboratory.

■ ASSOCIATED CONTENT

S **Supporting Information.** Experimental protocols for operon cloning, molecule production, and isolation as well as NMR

spectra and structural characterization details for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author
sbrady@rockefeller.edu

Author Contributions

[†]These authors contributed equally.

■ ACKNOWLEDGMENT

We thank Emil Lobkovsky at the Cornell X-ray Crystallography Facility for his assistance. This work was supported by the Northeast Biodefense Center (US4-AI057158). Phosphodiesterase assays were run by BPS Biosciences (San Diego, CA).

■ REFERENCES

- (1) Bassler, B. L.; Losick, R. *Cell* **2006**, *125*, 237–246.
- (2) Njoroge, J.; Sperandio, V. *EMBO Mol. Med.* **2009**, *1*, 201–210.
- (3) (a) Zerikly, M.; Challis, G. L. *ChemBioChem* **2009**, *10*, 625–633. (b) Hertweck, C. *Nat. Chem. Biol.* **2009**, *5*, 450–452. (c) Li, M. H. T.; Ung, P. M. U.; Zajkowski, J.; Garneau-Tsodikova, S.; Sherman, D. H. *BMC Bioinf.* **2009**, *10*, No. 185. (d) Van Lanen, S. G.; Shen, B. *Curr. Opin. Microbiol.* **2006**, *9*, 252–260. (e) Bode, H. B.; Muller, R. *Angew. Chem., Int. Ed.* **2005**, *44*, 6828–6846. (f) Peric-Concha, N.; Long, P. F. *Drug Discovery Today* **2003**, *8*, 1078–1084.
- (4) Adler, N. R.; Govan, B.; Cullinane, M.; Harper, M.; Adler, B.; Boyce, J. D. *FEMS Microbiol. Rev.* **2009**, *33*, 1079–1099.
- (5) Song, Y.; Xie, C.; Ong, Y. M.; Gan, Y. H.; Chua, K. L. *J. Bacteriol.* **2005**, *187*, 785–790.
- (6) Duerkop, B. A.; Varga, J.; Chandler, J. R.; Peterson, S. B.; Herman, J. P.; Churchill, M. E.; Parsek, M. R.; Niernan, W. C.; Greenberg, E. P. *J. Bacteriol.* **2009**, *191*, 3909–3918.
- (7) Seyedsayamdost, M. R.; Chandler, J. R.; Blodgett, J. A.; Lima, P. S.; Duerkop, B. A.; Oinuma, K.; Greenberg, E. P.; Clardy, J. *Org. Lett.* **2010**, *12*, 716–719.
- (8) Brady, S. F.; Bauer, J. D.; Clarke-Pearson, M. F.; Daniels, R. *J. Am. Chem. Soc.* **2007**, *129*, 12102–12103.
- (9) Some operons present in both *B. pseudomallei* K96243 and its close relative *B. thailandensis* E264 were amplified from *B. thailandensis* genomic DNA.
- (10) BPSS2111–2113 was originally cloned as what was thought to be a three-gene operon. However, on closer inspection, the second open reading frame (ORF) contains a series of mutations that cause it to be a truncated pseudogene. Most sequenced *B. pseudomallei* genomes available in GenBank contain mutations in this gene that introduce premature stop codons. Cultures of *P. aeruginosa* transformed with BPSS2111–2113, BPSS2111–2112, or BPSS2111 alone produce the same set of clone-specific compounds. BPSS2111, a predicted FAD-dependent monooxygenase, is therefore necessary and sufficient to confer the production of all three metabolites (**5**, **6**, and **7**) to *P. aeruginosa*. To confirm the role of this single ORF in the production of these metabolites, we introduced a BPSS2111 expression construct into a second host, *Burkholderia graminis* C4D1M. As seen in *P. aeruginosa*, the expression of BPSS2111 alone was sufficient to generate **5**, **6**, and **7** in *B. graminis*. BPSS2111 homologues are found in a number of sequenced bacterial genomes. Additional studies are required in order to determine the exact biosynthetic origin of this family of metabolites. It is possible that BPSS2111 generates **5**, which appears first in the culture broth, and that host enzymes add the thiomethyl groups. None of the compounds produced by the BPSS2111–2113 operon closely resemble previously described metabolites with well-defined functions.
- (11) (a) Kim, H. S.; Schell, M. A.; Yu, Y.; Ulrich, R. L.; Sarria, S. H.; Niernan, W. C.; DeShazer, D. *BMC Genomics* **2005**, *6*, No. 174. (b) Yu,

Y.; Kim, H. S.; Chua, H. H.; Lin, C. H.; Sim, S. H.; Lin, D.; Derr, A.; Engels, R.; DeShazer, D.; Birren, B.; Nierman, W. C.; Tan, P. *BMC Microbiol.* **2006**, *6*, No. 46.

(12) Glass, M. B.; Gee, J. E.; Steigerwalt, A. G.; Cavuoti, D.; Barton, T.; Hardy, R. D.; Godoy, D.; Spratt, B. G.; Clark, T. A.; Wilkins, P. P. *J. Clin. Microbiol.* **2006**, *44*, 4601–4604.

(13) (a) Balibar, C. J.; Howard-Jones, A. R.; Walsh, C. T. *Nat. Chem. Biol.* **2007**, *3*, 584–592. (b) Schneider, P.; Weber, M.; Hoffmeister, D. *Fungal Genet. Biol.* **2008**, *45*, 302–309.

(14) Thongdee, M.; Gallagher, L. A.; Schell, M.; Dharakul, T.; Songsivilai, S.; Manoil, C. *Appl. Environ. Microbiol.* **2008**, *74*, 2985–2989.

(15) Nakagawa, F.; Takahashi, S.; Naito, A.; Sato, S.; Iwabuchi, S.; Tamura, C. *J. Antibiot. (Tokyo)* **1984**, *37*, 10–12.

(16) Terferol has also been reported to be a parasite-specific cGMP-dependent protein kinase inhibitor. See: Zhang, C.; Ondeyka, J. G.; Herath, K. B.; Guan, Z.; Collado, J.; Pelaez, F.; Leavitt, P. S.; Gurnett, A.; Nare, B.; Liberator, P.; Singh, S. B. *J. Nat. Prod.* **2006**, *69*, 710–712.

(17) (a) Omori, K.; Kotera, J. *Circ. Res.* **2007**, *100*, 309–327. (b) Press, N. J.; Banner, K. H. *Prog. Med. Chem.* **2009**, *47*, 37–74 and references therein.

(18) Houslay, M. D.; Schafer, P.; Zhang, K. Y. *Drug Discovery Today* **2005**, *10*, 1503–1519.

(19) Soares, A. C.; Souza, D. G.; Pinho, V.; Vieira, A. T.; Barsante, M. M.; Nicoli, J. R.; Teixeira, M. *Br. J. Pharmacol.* **2003**, *140*, 855–862.

(20) Nelson, S.; Summer, W. R.; Jakab, G. J. *Am. Rev. Respir. Dis.* **1985**, *131*, 923–927.

(21) Wild-type PDE activities are gated by spatiotemporal regulation within cell-signaling niches, whose efficacy is normally low ($K_m \approx 1–10 \mu\text{M}$; see ref 17b), providing locally concentrated PDE inhibitors with the potential ability to disrupt normal PDE signaling in localized cell populations.